Every DEF 14A that Lesaka Technologies, Inc. (LSAK) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow LSAK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LSAK filings page.
Lesaka Technologies, Inc. asks shareholders to vote at its November 18, 2026 annual meeting on 11 director nominees, ratification of KPMG, Inc. for the fiscal year ending June 30, 2027, and an advisory vote on named executive officer compensation. The Board recommends voting FOR each proposal. Nine directors are standing for re-election, while Carolina Lacerda and James Oates are standing for election for the first time. Each common share carries one vote; 85,794,723 common shares were outstanding as of September 25, 2026, the record date.
For fiscal 2026, cash incentive award payments were $354,875 for Group Chief Financial Officer Dan Smith, $400,000 for Head of Corporate Development and Mergers & Acquisitions Steven Heilbron, $300,000 for Group Chief Operating Officer Naeem Kola, and $354,874 for Chief Executive Officer: Southern Africa Lincoln Mali. On February 25, 2026, Mali was awarded a one-off bonus of ZAR 3,500,000 and 150,000 restricted shares. The shares vest in three equal tranches over three years beginning February 25, 2027, subject to continuous employment through each vesting date. The say-on-pay vote is non-binding.
Lesaka Technologies has called a special shareholder meeting to approve a one-time stock option grant for Executive Chairman Ali Mazanderani under Nasdaq Listing Rule 5635(c). The Option Award covers 1,000,000 options to buy common stock at $5.00 per share, above the market price on the May 12, 2026 board approval date.
The options vest only if he remains employed through April 1, 2028, and can be exercised between April 1, 2029 and April 1, 2030. There is no acceleration on termination, death, disability or change in control if vesting has not occurred. If shareholders do not approve the agreement, the award is automatically forfeited.
As of the record date, Lesaka had 85,796,794 shares outstanding and Mazanderani beneficially owned 2,948,538 shares, plus vested options from prior awards. If he exercised both this new award and his existing options in full, his ownership would represent about 8.7% of outstanding shares. The company estimates grant-date fair value of the new award at about $1.6 million, with expected stock-based compensation expense of $0.9 million in the year ending June 30, 2027 and $0.7 million in 2028.